Abatacept in Immune Checkpoint Inhibitor Myocarditis
This study is for people who have heart inflammation (myocarditis) that has developed after receiving certain cancer treatments called immune checkpoint inhibitors. These cancer treatments work by boosting your immune system, but sometimes they can also cause it to attack the heart. We already know that standard treatments like steroids don't always fully prevent serious heart problems in these cases. This study aims to find out if an additional medicine called abatacept, given alongside steroids, can help reduce the risk of serious heart issues like heart attacks, dangerous heart rhythms, or heart failure. Participants will either receive abatacept or a dummy drug (placebo) to see which is more effective.
Auf einen Blick
Worum geht es in dieser Studie?
This study is looking at a new way to treat a specific type of heart inflammation, called myocarditis. This heart issue can sometimes happen to people undergoing certain cancer treatments. These treatments, known as immune checkpoint inhibitors, are very good at helping your body fight cancer, but occasionally they can cause your immune system to mistakenly attack other parts of the body, including your heart. When this happens, it's a serious condition.
Even with the best standard treatments currently available, such as high-dose steroids, people with this type of myocarditis can still experience serious heart problems. These might include things like a heart attack, dangerously fast or slow heartbeats, or the heart struggling to pump blood properly. Researchers have noticed that these serious heart problems are much more common in people with myocarditis caused by cancer treatment compared to other types of myocarditis.
That's where this study comes in. It's investigating if an additional medicine called abatacept can make a difference. Abatacept works by calming down parts of the immune system that might be overactive. Early research and some patient information suggest that abatacept could help reduce damage to the heart and improve outcomes for people with this type of myocarditis. This study aims to confirm these findings in a careful and organised way, comparing abatacept with a dummy drug (placebo) to see if it truly helps reduce serious heart problems when given alongside standard steroid treatment.
Wichtige Erkenntnisse
- This study evaluates abatacept for heart inflammation (myocarditis) from cancer treatment.
- It aims to reduce serious heart problems in people with this condition.
- Participants will receive either abatacept or a dummy drug alongside standard care.
- The study includes careful monitoring during hospitalisation and follow-up.
- It's a 'double-blind' study, meaning no one knows who gets the active drug.
- Die Teilnahme ist freiwillig, und Sie können jederzeit zurücktreten.
Wer könnte berechtigt sein?
To be able to take part in this study, you need to meet a few important conditions. Firstly, you must be 18 years or older. You also need to have given your consent, meaning you understand the study and agree to participate. If you're too unwell to give consent, a family member or legal guardian might be able to do so for you, as allowed by local rules.
Crucially, you must have recently (within the last six months) received an immune checkpoint inhibitor for cancer treatment. This study is specifically for people whose myocarditis developed after this type of cancer treatment. You also need to have a clear diagnosis of myocarditis and be in hospital at the time you join the study.
Finally, your heart needs to show signs of ongoing injury, which doctors will check using a blood test called troponin. This blood test result needs to be significantly higher than normal, indicating that your heart is still affected, and this high level must have been noted recently. You also need to be receiving or about to start a high dose of a steroid medication called solumedrol for your myocarditis.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Have you recently received a type of cancer treatment called an 'immune checkpoint inhibitor'?
- Have you been diagnosed with myocarditis (heart inflammation)?
- Are you currently in hospital for your myocarditis?
- Are you receiving or about to start high-dose steroid treatment for your heart inflammation?
- Does your recent blood test show ongoing signs of heart injury (high troponin level)?
Was beinhaltet die Teilnahme?
If you join this study, you will either receive the study drug abatacept or a dummy drug (placebo) through an injection, alongside the standard steroid treatment your doctors are already giving you. Neither you nor your doctors will know whether you are receiving abatacept or the placebo. You'll need to remain in hospital for a period, where doctors will closely monitor your heart and overall health. This will involve regular blood tests, heart scans, and checks on your heart's electrical activity (ECGs) to see how you are responding to treatment.
During your time in the study, medical staff will carefully watch for any changes in your condition or any side effects. After you leave the hospital, there will be follow-up appointments to continue monitoring your heart health and ensure your recovery is progressing well. The total duration of your participation in the study will involve initial treatment while in hospital and then follow-up appointments over a period of time, which your study doctor will explain in detail.
Potenzielle Risiken und Vorteile
Standorte (31)
- Cedars-Sinai Medical CenterVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten· Rekrutierung
- Universität von Kalifornien, Los AngelesVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten· Rekrutierung
- MedStar Health Research Institute, Georgetown UniversityVerifizierte PostleitzahlWashington D.C., Vereinigte Staaten· Rekrutierung
- Moffitt KrebszentrumVerifizierte PostleitzahlTampa, Vereinigte Staaten· Rekrutierung
- Universität von ChicagoVerifizierte PostleitzahlChicago, Vereinigte Staaten· Rekrutierung
- Franciscan HealthVerifizierte PostleitzahlIndianapolis, Vereinigte Staaten· Rekrutierung
- University of Kansas Medical CenterVerifizierte PostleitzahlKansas City, Vereinigte Staaten· Rekrutierung
- University of KentuckyVerifizierte PostleitzahlLexington, Vereinigte Staaten· Rekrutierung
- Maine HealthVerifizierte PostleitzahlPortland, Vereinigte Staaten· Rekrutierung
- Johns HopkinsVerifizierte PostleitzahlBaltimore, Vereinigte Staaten· Rekrutierung
- Massachusetts General HospitalVerifizierte PostleitzahlBoston, Vereinigte Staaten· Rekrutierung
- Beth Israel Deaconess Medical CenterVerifizierte PostleitzahlBoston, Vereinigte Staaten· Rekrutierung
Häufige Fragen
What is myocarditis?
Myocarditis is inflammation of the heart muscle, which can make it harder for your heart to pump blood effectively.
What are immune checkpoint inhibitors?
These are a type of cancer treatment that helps your body's own immune system fight cancer cells more effectively.
What is abatacept?
Abatacept is a medication that helps to quiet down an overactive immune system. It's used for some autoimmune conditions.
Will I know if I'm getting the real drug or a dummy drug?
No, neither you nor your doctors will know if you are receiving abatacept or the placebo (dummy drug) during the study. This helps ensure fair results.
What if my condition gets worse during the study?
You will be closely monitored by medical staff, and if your condition changes or worsens, your doctors will provide appropriate medical care and may remove you from the study if it's in your best interest.
Wie Sie mehr erfahren können
Hannah K Gilman, MS
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.